Prism Suite
Prism Suite is powered by proprietary digital biomarkers developed specifically for mental health intervention. Offering two protocols and a toolbox to guide patient engagement, Prism can bring a new revenue-generating service line to your interventional psychiatry clinic.
All you need is a small quiet room, stationary table and chair, wired Internet connection and a trained Prism operator to administer the patient sessions. GrayMatters Health will take care of installation and setup, onboarding and ongoing support.
Features
PTSD protocol
(FDA 510(k) cleared). A prescribed adjunct treatment for post-traumatic stress disorder (PTSD), Prism uses the amygdala-based biomarker to help patients regulate brain activity associated with PTSD symptoms. This treatment does not require talking about or re-visiting traumatic events or taking additional medications.
​
In the clinic, patients explore and develop their own a mental strategy – a memory, experience or feeling to get the animated characters in the simulation to sit down and lower their voices. This mental strategy can then be used to manage PTSD symptoms in daily life.
Depression protocol
(FDA exempt – general wellness). In the clinic, patients learn to up-regulate the reward-system biomarker by interacting with a computer simulation developed specifically for depression. This experience allows them to explore and develop a mental strategy – a memory, experience or feeling of happiness, motivation, anticipation or accomplishment to get the animated character in the simulation to do an activity with her dog.
Insights
A new tool for the Prism specialist and clinician. Insights delivers data-based observations to help understand each patient’s performance and progress to improve their overall Prism experience. Insights also provides potential topics for discussion and best practices to support the patient-provider relationship.
PTSD
The Prism for PTSD multi-center clinical study demonstrated the following results 3 months after the 15-session regimen (5 months from baseline):
-
67% of patients overall demonstrated clinically significant symptom improvement as measured by CAPS-5.
-
Significant improvement in sleep, as measured by PHQ-9 and CAPS-5.
-
32% experienced remission.
-
90% patient compliance.
Depression
The pilot study to evaluate Prism for Depression was conducted at three medical centers in Israel, involving an ITT group of 44 and a per protocol group of 34 subjects. In this study, the treatment regimen consisted of 10 sessions. Although treatment effects were observed after 10 sessions, a 15-session regimen is recommended to achieve robust and sustained clinical outcomes.
The study demonstrated:
​
-
76% of participants experienced a significant reduction in depressive symptoms, with an average reduction
of 7.82 in HDRS and 6.32 in SHAPS-C -
38% response rate of 50% reduction
in symptoms -
32% remission rate
Safety: A majority of the reported adverse events were mild and self-resolved
immediately after the session.
Scheduling Patients
-
15 sessions, over 8 weeks
or as determined by provider. -
Each session lasts about 45-minutes.
-
Booster sessions, as needed.
Prism includes a laptop with the installed Prism software (two protocols and Insights tool), computer monitor, and cloud services. Provided separately is an FDA-cleared, off-the-shelf wireless EEG headset (g.Nautilus PRO).
Prism requires a small quiet room, stationary table and chair, wired Internet connection and a trained Prism healthcare professional to monitor the patient sessions.
During most of the treatment itself, it is possible to monitor the patient session from a remote computer in a separate room.
Training is provided by the GMH team and requires approximately four hours.